HYDROXYETHYL STARCH 130/0.4

Summary

Hydroxyethyl Starch 130/0.4 (CHEMBL2108701) is an approved unknown; indicated across 6 conditions including hip fracture and coronary artery disorder.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Unknown
• Indications: 6 conditions
• Clinical trials: 18

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2108701
Name	HYDROXYETHYL STARCH 130/0.4
Type	Unknown
Max phase	4

Also known as: HES 130/0.4, HES-130/0.4, Hydroxyethyl starch 130/0.4, Volulyte, Voluven, HYDROXYETHYL STARCH 130/0.4

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

6 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
hip fracture	3	MONDO:0005327	EFO:0003964
coronary artery disorder	2	MONDO:0005010	EFO:0001645
hypotensive disorder	0	MONDO:0005468	EFO:0005251
pulmonary edema	0	MONDO:0006932	EFO:1001134

2 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 18.

Phase distribution

Phase	Trials
Not specified	8
PHASE4	7
PHASE3	1
PHASE2	1
EARLY_PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT06663254	PHASE4	NOT_YET_RECRUITING	Safety and Efficacy of Perioperative Volume Replacement with Volulyte 6% in Moderate-to-high Cardiovascular Risk Patients Having Major Abdominal Surgery
NCT01689506	PHASE4	TERMINATED	Fluid Resuscitation in Patients Suffering From Burns Injury
NCT02312999	PHASE4	COMPLETED	Crystalloids or Colloids for Goal-directed Fluid Therapy With Closed-loop Assistance in Major Surgery
NCT02587078	PHASE4	WITHDRAWN	Volume Therapy With Crystalloids and Colloids and Hemodynamic Monitoring in Patients With Severe Sepsis
NCT03278548	PHASE4	COMPLETED	Safety and Efficacy of 6% Hydroxyethyl Starch (HES) Solution Versus an Electrolyte Solution in Patients Undergoing Elective Abdominal Surgery
NCT03338218	PHASE4	COMPLETED	Safety and Efficacy of a 6% Hydroxyethyl Starch (HES) Solution Versus an Electrolyte Solution in Trauma Patients
NCT03420261	PHASE4	COMPLETED	Hemostasis Evolution During Fluid Loading in Abdominal Surgery. Effects of Fluid Choice: Saline Versus Hydroxyethyl Starch (HAEMO Study)
NCT00444262	PHASE3	TERMINATED	Stroke Volume Optimisation in Patients With Hip Fracture
NCT00317512	PHASE2	COMPLETED	Pilot Study of Hemoglobin Based Oxygen Therapeutics in Elective Coronary Revascularization
NCT03465943	EARLY_PHASE1	UNKNOWN	Different Preloads for Prevention of Hypotension in Patients Undergoing Elective CS Under Intrathecal Anesthesia
NCT07329660	Not specified	NOT_YET_RECRUITING	Crystalloid vs Colloid for Hemodynamics During Anesthesia Induction in TAVR Patients
NCT01452581	Not specified	TERMINATED	Liberal Versus Restrictive Transfusion During Symptomatic Moderate Anemia After Hip Arthroplasty
NCT01512628	Not specified	COMPLETED	Rotational Thromboelstometry (ROTEM) change_colloid_total Hip Replacement Arthroplasty
NCT01644084	Not specified	COMPLETED	A Comparison Between 5% Albumin and 6% Hydroxyethyl Starch 130/0.4 in Priming Solution for Cardiopulmonary Bypass and Post-bypass Maintenance Fluid in High-risk Patients
NCT01849757	Not specified	WITHDRAWN	Comparison of Priming Constituents in Patients Undergoing CPB Assisted Cardiac Surgery: HES 130/0.4 or Albumin 5%
NCT02034682	Not specified	COMPLETED	The Effect of Hydroxyethylstarch 6% 130/0.4 in a Balanced Electrolyte Solution (Volulyte®) Compared to Gelatine (Geloplasma®) on Microvascular Reactivity and Tissue Oxygen Saturation During Haemodilution Measured With Near-infrared Spectroscopy
NCT02701582	Not specified	COMPLETED	Goal-Directed Intraoperative Fluid Management Using FloTrac© Monitoring in High-Risk Neurosurgical Patients
NCT05475886	Not specified	UNKNOWN	6% Hydroxyethyl Starch (130/0.4) Coload for Postspinal Anesthesia Hypotension

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).